San Francisco, CA - 89bio, Inc., a clinical-stage biopharmaceutical company with a laser focus on delivering cutting-edge therapies for liver and cardio-metabolic diseases, is making waves. The company's lead product candidate, pegozafermin, is the object of much excitement in the industry due to its remarkable potential for treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia. Pegozafermin is a glycoPEGylated analog of fibroblast growth factor 21 that has caught the attention of many observers in the field due to its breathtaking clinical results. Founded in 2018, 89bio, Inc. has quickly established itself as a leader in the field of biopharmaceuticals. Headquartered in San Francisco, the company is leveraging cutting-edge research and development to drive the next generation of anti-liver and cardio-metabolic disease treatments. With a keen eye on the market, 89bio, Inc. is a company to watch closely as it continues to make strides in the field of biopharmaceuticals.
89Bio's ticker is ETNB
The company's shares trade on the NASDAQ stock exchange
They are based in San Francisco, California
There are 11-50 employees working at 89Bio
It is 89bio.com
89Bio is in the Healthcare sector
89Bio is in the Biotechnology industry
The following five companies are 89Bio's industry peers: